The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 301–400 of 1,158
Jedynak, B., Lang, A., Liu, B., Katz, E., Zhang, Y., Wyman, B. T., Raunig, D. L., Jedynak, C. P., Caffo, B. S., & Prince, J. L. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.07.059 · Cited by 253
Dubois, B., Epelbaum, S., Nyasse, F., Bakardjian, H., Gagliardi, G. P., Uspenskaya, O., Houot, M., Lista, S., Cacciamani, F., Potier, M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30029-2 · Cited by 253
Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings
O’Bryhim, B. E., Apte, R. S., Kung, N. H., Coble, D. W., & Stavern, G. P. V. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3556 · Cited by 253
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bbe · Cited by 252
Self-citationManagement of mild cognitive impairment (MCI): The need for national and international guidelines
Kasper, S. F., Bancher, C., Eckert, A., Förstl, H., Frölich, L., Hort, J., Korczyn, A. D., Kressig, R. W., Levin, O. S., & Palomo, M. S. M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1696473 · Cited by 252
Bakkour, A., Morris, J. C., Wolk, D. A., & Dickerson, B. C. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.02.059 · Cited by 251
Retinal thickness in Alzheimer's disease: A systematic review and meta‐analysis
den Haan, J., Verbraak, F. D., Visser, P. J., & Bouwman, F. H. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.014 · Cited by 250
Meghdadi, A. H., Karić, M. S., McConnell, M., Rupp, G., Richard, C., Hamilton, J. M., Salat, D. H., & Berka, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244180 · Cited by 251
Subjective Cognitive Complaints Contribute to Misdiagnosis of Mild Cognitive Impairment
Edmonds, E. C., Delano-Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771400068x · Cited by 249
Risk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects
Rodrigue, K. M., Rieck, J. R., Kennedy, K. M., Devous, M. D., Diaz-Arrastia, R., & Park, D. C. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1342 · Cited by 249
Self-citationClinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt231 · Cited by 249
Self-citationPistollato, F., Iglesias, R. C., Ruiz, R., Aparicio, S., Crespo, J., Lopez, L. D., Manna, P. P., Giampieri, F., & Battino, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.012 · Cited by 247
Association of Retinal Neurodegeneration on Optical Coherence Tomography With Dementia
Mutlu, Ü., Colijn, J. M., Ikram, M. A., Bonnemaijer, P. W. M., Licher, S., Wolters, F. J., Tiemeier, H. W., Koudstaal, P. J., Klaver, C. C. W., & Ikram, M. K. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1563 · Cited by 247
Blood neuro‐exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage
Jia, L., Zhu, M., Kong, C., Pang, Y., Zhang, H., Qiu, Q., Wei, C., Tang, Y., Wang, Q., Li, Y., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12166 · Cited by 247
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004667 · Cited by 245
Cardoso, M. J., Leung, K. K., Marc Modat, A., Shiva Keihaninejad, A., Cash, D. M., Barnes, J., Fox, N. C., & Sebastien Ourselin, A. (2013) · Medical Image Analysis · doi:10.1016/j.media.2013.02.006 · Cited by 246
Ishii, M., & Iadecola, C. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.016 · Cited by 245
EEG evidence of compensatory mechanisms in preclinical Alzheimer’s disease
Gaubert, S., Raimondo, F., Houot, M., Corsi, M., Naccache, L., Sitt, J. D., Hermann, B., Oudiette, D., Gagliardi, G. P., Habert, M., et al. (2019) · Brain · doi:10.1093/brain/awz150 · Cited by 243
Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease
Fjell, A. M., McEvoy, L. K., Holland, D., Dale, A. M., Walhovd, K. B., & Initiative, A. D. N. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5506-12.2013 · Cited by 242
El–Sappagh, S., Abuhmed, T., Islam, S. M. R., & Kwak, K. S. (2020) · Neurocomputing · doi:10.1016/j.neucom.2020.05.087 · Cited by 244
Neuronal cell death mechanisms in Alzheimer’s disease: An insight
Goel, P., Chakrabarti, S., Goel, K., Bhutani, K., Chopra, T., & Bali, S. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.937133 · Cited by 248
Nutrition for the ageing brain: Towards evidence for an optimal diet
Vauzour, D., Camprubi-Robles, M., Miquel-Kergoat, S., Andres-Lacueva, C., Bánáti, D., Barberger-Gateau, P., Bowman, G. L., Caberlotto, L., Clarke, R., Hogervorst, E., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.010 · Cited by 241
Kapogiannis, D., Mustapic, M., Shardell, M. D., Berkowitz, S. T., Diehl, T. C., Spangler, R. D., Tran, J., Lazaropoulos, M. P., Chawla, S., Gulyani, S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2462 · Cited by 241
Falahati, F., Westman, E., & Simmons, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131928 · Cited by 241
Davis, M. R., O`Connell, T., Johnson, S., Cline, S. K., Merikle, E. P., Martényi, F., & Simpson, K. N. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180119092427 · Cited by 241
Corriveau, R. A., Bosetti, F., Emr, M., Gladman, J. T., Koenig, J. I., Moy, C. S., Pahigiannis, K., Waddy, S. P., & Koroshetz, W. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0334-7 · Cited by 240
Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats
Latimer, C. S., Brewer, L. D., Searcy, J. L., Chen, K.-C., Popović, J., Kraner, S. D., Thibault, O., Blalock, E. M., Landfield, P. W., & Porter, N. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404477111 · Cited by 239
Early-Onset Familial Alzheimer's Disease (EOFAD)
Wu, L., Rosa‐Neto, P., Hsiung, G. R., Sadovnick, A. D., Masellis, M., Black, S. E., Jia, J., & Gauthier, S. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013949 · Cited by 240
Apathy associated with neurocognitive disorders: Recent progress and future directions
Lanctôt, K. L., Agüera-Ortíz, L., Brodaty, H., Francis, P. T., Geda, Y. E., Ismail, Z., Marshall, G. A., Mortby, M. E., Onyike, C. U., Padala, P. R., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.05.008 · Cited by 239
The future of Alzheimer's disease: The next 10 years
Hampel, H. J., Prvulovic, D., Teipel, S. J., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R. C., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 238
Outdoor Ambient Air Pollution and Neurodegenerative Diseases: the Neuroinflammation Hypothesis
Jayaraj, R. L., Rodriguez, E. A., Wang, Y., & Block, M. L. (2017) · Current Environmental Health Reports · doi:10.1007/s40572-017-0142-3 · Cited by 240
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 237
Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease
Roh, J. H., Jiang, H., Finn, M. B., Stewart, F. R., Mahan, T. E., Cirrito, J. R., Heda, A., Snider, B. J., Li, M., Yanagisawa, M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141788 · Cited by 237
Spatial Navigation in Preclinical Alzheimer’s Disease
Allison, S. L., Fagan, A. M., Morris, J. C., & Head, D. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150855 · Cited by 237
Self-citationMicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126423 · Cited by 236
Brain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236
Plant-Based Dietary Patterns, Plant Foods, and Age-Related Cognitive Decline
Rajaram, S., Jones, J., & Lee, G. J. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz081 · Cited by 235
Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O. C., & Sachpekidis, C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010632.pub2 · Cited by 235
Physical activity attenuates age-related biomarker alterations in preclinical AD
Okonkwo, O. C., Schultz, S. A., Oh, J. M., Larson, J., Edwards, D. F., Cook, D. B., Koscik, R. L., Gallagher, C. L., Dowling, N. M., Carlsson, C. M., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000964 · Cited by 235
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline
Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., Grundman, M., Sabbagh, M. N., Sadowsky, C., Fleisher, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661f74 · Cited by 235
Self-citationRole of Copper in the Onset of Alzheimer’s Disease Compared to Other Metals
Bagheri, S., Squitti, R., Haertlé, T., Siotto, M., & Saboury, A. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00446 · Cited by 235
Donovan, N. J., Amariglio, R. E., Zoller, A. S., Rudel, R. K., Gómez‐Isla, T., Blacker, D., Hyman, B. T., Locascio, J. J., Johnson, K. A., Sperling, R. A., et al. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.02.007 · Cited by 234
Self-citationPolitical drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis
Couteur, D. G. L., Doust, J. A., Creasey, H. M., & Brayne, C. (2013) · BMJ · doi:10.1136/bmj.f5125 · Cited by 234
Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores
Leonenko, G., Baker, E. A., Stevenson‐Hoare, J. O., Sierksma, A. S. R., Fiers, M. W. E. J., Williams, J. H., Strooper, B. D., & Escott‐Price, V. (2021) · Nature Communications · doi:10.1038/s41467-021-24082-z · Cited by 233
Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Jiang, T., Yu, J., Tian, Y., & Tan, L. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990155 · Cited by 231
Boyle, P. A., Yu, L., Wilson, R. S., Gamble, K. J., Buchman, A. S., & Bennett, D. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043647 · Cited by 230
Self-citationWierenga, C. E., Hays, C. C., & Zlatar, Z. Z. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141467 · Cited by 229
Harvard Aging Brain Study: Dataset and accessibility
Dagley, A. S., LaPoint, M. R., Huijbers, W., Hedden, T., McLaren, D. G., Chatwal, J. P., Papp, K. V., Amariglio, R. E., Blacker, D., Rentz, D. M., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.03.069 · Cited by 229
Self-citationJessen, F., Spottke, A. E., Boecker, H., Brosseron, F., Büerger, K., Catak, C., Fließbach, K., Franke, C., Fuentes, M., Heneka, M. T., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0314-2 · Cited by 229
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H. H., Reus, L. M., van der Lee, S. J., Wesenhagen, K. E. J., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00550-7 · Cited by 237
Aging and mental health in the decade ahead: What psychologists need to know
Karel, M. J., Gatz, M., & Smyer, M. A. (2012) · American Psychologist · doi:10.1037/a0025393 · Cited by 228
Wen, M. M., El-Salamouni, N. S., El-Refaie, W. M., Hazzah, H. A., Ali, M. M., Tosi, G., Farid, R. M., Blanco‐Prieto, M. J., Billa, N., & Hanafy, A. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.025 · Cited by 228
Vitamin D and Neurological Diseases: An Endocrine View
Somma, C. D., Scarano, E., Barrea, L., Zhukouskaya, V. V., Savastano, S., Mele, C., Scacchi, M., Aimaretti, G., Colao, A., & Marzullo, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112482 · Cited by 229
Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer’s Disease
Ehrenberg, A. J., Suemoto, C. K., Resende, E. D. P. F., Petersen, C., Leite, R. E. P., Rodriguez, R. D., Ferretti‐Rebustini, R. E. D. L., You, M. Y., Oh, J. Y., Nitríni, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180688 · Cited by 233
Wu, L., Han, Y., Zheng, Z., Peng, G., Liu, P., Yue, S., Zhu, S., Chen, J., Lv, H., Shao, L., et al. (2021) · Nutrients · doi:10.3390/nu13010228 · Cited by 227
Role of EEG as Biomarker in the Early Detection and Classification of Dementia
Al-Qazzaz, N. K., Ali, S. H. M., Ahmad, S. A., Chellappan, K., Islam, M. S., & Escudero, J. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/906038 · Cited by 227
Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging
Solfrizzi, V., Scafato, E., Frisardi, V., Seripa, D., Logroscino, G., Maggi, S., Imbimbo, B. P., Galluzzo, L., Baldereschi, M., Gandin, C., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.223 · Cited by 227
Ladenbauer, J., Ladenbauer, J., Külzow, N., de Boor, R., Avramova, E., Grittner, U., & Flöel, A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0260-17.2017 · Cited by 227
Mitochondrial dysfunction in microglia: a novel perspective for pathogenesis of Alzheimer’s disease
Li, Y., Xia, X., Wang, Y., & Zheng, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02613-9 · Cited by 231
Imaging markers for Alzheimer disease
Frisoni, G. B., Bocchetta, M., Chételat, G., Rabinovici, G. D., de Leon, M. J., Kaye, J. A., Reiman, E. M., Scheltens, P., Barkhof, F., Black, S. E., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d86e8 · Cited by 226
Self-citationShamrat, F. M. J. M., Akter, S., Azam, S., Karim, A., Ghosh, P., Tasnim, Z., Hasib, K. M., Boer, F. D., & Ahmed, K. (2023) · IEEE Access · doi:10.1109/access.2023.3244952 · Cited by 226
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Yin, L., Thambisetty, M., Troncoso, J. C., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0282-4 · Cited by 225
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
BackgroundJack, C. R., Barkhof, F., Bernstein, M. A., Cantillon, M., Cole, P. E., DeCarli, C. S., Dubois, B., Duchesne, S., Fox, N. C., Frisoni, G. B., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.04.007 · Cited by 225
Self-citationEvidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 225
Self-citationDetecting Anatomical Landmarks for Fast Alzheimer’s Disease Diagnosis
Zhang, J., Gao, Y., Gao, Y., Munsell, B. C., & Shen, D. G. (2016) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2016.2582386 · Cited by 225
Dementia Prevention and Treatment
Reuben, D. B., Kremen, S. A., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 225
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage
Poil, S., de Haan, W., van der Flier, W. M., Mansvelder, H. D., Scheltens, P., & Linkenkaer‐Hansen, K. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00058 · Cited by 224
Sex and gender differences in cognitive resilience to aging and Alzheimer's disease
Arenaza‐Urquijo, E. M., Boyle, R., Casaletto, K., Anstey, K. J., Vila‐Castelar, C., Colverson, A., Palpatzis, E., Eissman, J. M., Kheng Siang Ng, T., Raghavan, S., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13844 · Cited by 223
Roberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223
Self-citationDjelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bièche, I., Marquer, C., Chali, F., Ayciriex, S., Auzeil, N., et al. (2015) · Brain · doi:10.1093/brain/awv166 · Cited by 223
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Self-citationRowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222
Self-citationValidation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting
Perani, D., Rosa, P. A. D., Cerami, C., Gallivanone, F., Fallanca, F., Vanoli, E. G., Panzacchi, A., Nobili, F. M., Pappatà, S., Marcone, A., et al. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.009 · Cited by 222
Rabin, J. S., Schultz, A. P., Hedden, T., Viswanathan, A., Marshall, G. A., Kilpatrick, E., Klein, H., Buckley, R. F., Yang, H.-S., Properzi, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1123 · Cited by 221
Self-citationLifespan brain activity, β-amyloid, and Alzheimer's disease
Jagust, W. J., & Mormino, E. C. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.09.004 · Cited by 221
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, J., Wang, M., Moghekar, A., Miller, M. I., & Albert, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.002 · Cited by 221
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220
Self-citationRelation of neuropathology to cognition in persons without cognitive impairment
Bennett, D. A., Wilson, R. S., Boyle, P. A., Buchman, A. S., & Schneider, J. A. (2012) · Annals of Neurology · doi:10.1002/ana.23654 · Cited by 220
Self-citationFluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 221
Disrupted structural and functional brain networks in Alzheimer's disease
Dai, Z., Lin, Q., Li, T., Wang, X., Yuan, H., Yu, X., Yong He, A., & Wang, H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.11.005 · Cited by 222
Lleó, A., Núñez-Llaves, R., Alcolea, D., Chiva, C., Balateu-Paños, D., Colom-Cadena, M., Gomez-Giro, G., Muñoz, L., Querol-Vilaseca, M., Pegueroles, J., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra118.001290 · Cited by 219
Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease
Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease
Lim, Y. Y., Maruff, P. T., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Lautenschlager, N. T., Szoeke, C. E. I., Martins, R. N., Masters, C. L., et al. (2013) · Brain · doi:10.1093/brain/awt286 · Cited by 219
Self-citationAmyloid burden and neural function in people at risk for Alzheimer's Disease
Johnson, S. C., Christian, B. T., Okonkwo, O. C., Oh, J. M., Harding, S., Xu, G., Hillmer, A. T., Wooten, D. W., Murali, D., Barnhart, T. E., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.028 · Cited by 218
Nobili, F. M., Arbizu, J., Bouwman, F. H., Drzezga, A. E., Agosta, F., Nestor, P. J., Walker, Z., Boccardi, M., & the EANM‐EAN Task Force for the Prescription of FDG‐PET for Dementing Neurodegenerative Disorders (2018) · European Journal of Neurology · doi:10.1111/ene.13728 · Cited by 220
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery
Shirk, S. D., Mitchell, M. B., Shaughnessy, L. W., Sherman, J. C., Locascio, J. J., Weıntraub, S., & Atri, A. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt94 · Cited by 217
Staging in bipolar disorder: from theoretical framework to clinical utility
Berk, M., Post, R., Ratheesh, A., Gliddon, E., Singh, A., Vieta, E., Carvalho, A. F., Ashton, M. M., Berk, L., Cotton, S. M., et al. (2017) · World Psychiatry · doi:10.1002/wps.20441 · Cited by 216
Early detection of Alzheimer's disease using PiB and FDG PET
Cohen, A. D., & Klunk, W. E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.001 · Cited by 216
Disrupted Small-World Brain Networks in Moderate Alzheimer's Disease: A Resting-State fMRI Study
Zhao, X., Liu, Y., Wang, X., Liu, B., Xi, Q., Guo, Q., Jiang, H., Jiang, T., & Wang, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033540 · Cited by 215
Ritchie, C. W., Smailagic, N., Noel-Storr, A. H., Ukoumunne, O. C., Ladds, E. C., & Martin, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010803.pub2 · Cited by 217
Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo
Macauley, S. L., Stanley, M., Caesar, E. E., Yamada, S. A., Raichle, M. E., Perez, R., Mahan, T. E., Sutphen, C. L., & Holtzman, D. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79742 · Cited by 218
Regional brain stiffness changes across the Alzheimer's disease spectrum
Murphy, M. C., Jones, D. T., Jack, C. R., Glaser, K. J., Senjem, M. L., Manduca, A., Felmlee, J. P., Carter, R. E., Ehman, R. L., & Huston, J. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.12.007 · Cited by 215
Self-citationCurrent advances in digital cognitive assessment for preclinical Alzheimer's disease
Öhman, F., Hassenstab, J., Berron, D., Schöll, M., & Papp, K. V. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12217 · Cited by 214
Vitamin B1 (thiamine) and dementia
Gibson, G. E., Hirsch, J. A., Fonzetti, P., Jordan, B. D., Cirio, R. T., & Elder, J. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13031 · Cited by 214
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
